The investigators propose to create a database at the regional level, the principle is to include all patients in whom a mutation was detected from a single platform (Lille). The creation of this regional cohort, smaller than the national cohort of Biomarkers France, will perform a more comprehensive collection of clinical data, and molecular monitoring data of patients included. To increase the completeness of the collection of information, it will not be based on voluntary prescribing clinician but will be largely carried out by CRA dedicated to this activity.

This is a prospective and retrospective study of a population of patients with mutated non-small cell lung cancer in the Nord Pas de Calais. Retrospective cohort will involve patients with main molecular abnormalities, identifiable from molecular biology platform CRRC, except EGFR and KRAS treated from September 2011 to February 2013.

Inclusion Criteria:

• Aged ≥ 18 years old
• Patient with non-small cell lung cancer
• Detected in the Nord Pas de Calais
• Monitored in the Nord Pas de Calais
• Patient must have signed a non-opposition form to the use of medical data

Exclusion Criteria:

- No identified mutation

Non-small cell lung cancer with mutation of the Nord Pas de Calais